Kidney dysfunction due to AA amyloidosis in a morbidly obese female.
amyloidosis
inflammation
obesity
serum amyloid A
Journal
Clinical nephrology. Case studies
ISSN: 2196-5293
Titre abrégé: Clin Nephrol Case Stud
Pays: Germany
ID NLM: 101638685
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
02
2023
accepted:
17
05
2023
medline:
3
8
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Kidneys are commonly involved in systemic amyloidosis. Systemic AA amyloidosis is known to be associated with states of chronic inflammation such as autoimmune conditions, chronic infections, and malignancies. Obesity is increasingly recognized to be a risk factor for low-grade, chronic inflammation. We report a 48-year-old female with morbid obesity who presented with unexplained persistent mild kidney dysfunction and low-grade proteinuria. Attempt at evaluating the cause of kidney dysfunction included performing kidney biopsy despite technical challenges. Kidney biopsy showed AA amyloidosis with predominant vascular deposition, explaining the absence of nephrotic-range proteinuria. Evaluation for secondary causes of systemic AA amyloidosis was negative. While our patient was treated with sleeve gastrectomy for morbid obesity with reasonable response, it is likely that ongoing chronic inflammation, reflected by her laboratory markers, resulted in AA amyloidosis. Treatment with anakinra, an interleukin-1 antagonist, led to improvement in the laboratory markers in the next 6 months, and her kidney function remained stable. This report highlights an important cause of kidney dysfunction in morbid obesity, an atypical presentation of AA amyloidosis, and emphasizes the value of kidney biopsy in such patients.
Identifiants
pubmed: 37533546
doi: 10.5414/CNCS111133
pmc: PMC10392626
doi:
Types de publication
Case Reports
Langues
eng
Pagination
121-125Informations de copyright
© Dustri-Verlag Dr. K. Feistle.
Déclaration de conflit d'intérêts
KDJ reports consultancy agreements with Secretome, George Clinicals, PMV pharmaceuticals, GSK, and Calliditas. KDJ reports honoraria from the American Society of Nephrology and UpToDate.com; reports serving on the editorial boards of American Journal of Kidney Diseases, CJASN, Clinical Kidney Journal, Journal of Onconephrology, Kidney International, and Nephrology Dialysis Transplantation; reports serving as Editor-in-Chief of ASN Kidney News and section editor for onconephrology for Nephrology Dialysis Transplantation. Figure 1Obesity-associated vascular and mesangial AA amyloidosis. Congo red staining highlights mainly vascular amyloid deposits and scant amyloid deposition in the mesangium (A) with apple-green birefringence under polarized light (B). The amyloid stained strongly with anti-SAA antibody (C). Table 1.Trend of inflammatory markers with treatment. ParameterInitial presentationAt 3 monthsAt 6 monthsC-reactive protein (mg/L)19.423.27.3Serum amyloid A protein (mg/L)26269Interleukin-6 (IU/L)493Interleukin-18 (IU/L)270254
Références
Annu Rev Pathol. 2015;10:321-44
pubmed: 25387054
Obes Surg. 2006 Mar;16(3):262-9
pubmed: 16545156
Ann Intern Med. 2006 Jan 3;144(1):21-8
pubmed: 16389251
Amyloid. 2018 Mar;25(1):37-45
pubmed: 29364741
N Engl J Med. 2007 Jun 7;356(23):2361-71
pubmed: 17554117
Dig Dis. 2012;30(2):148-53
pubmed: 22722429
Biochem Biophys Res Commun. 1988 Aug 30;155(1):112-7
pubmed: 3261980
Arteriosclerosis. 1990 Jul-Aug;10(4):493-6
pubmed: 2196039
Kidney Int. 2019 Mar;95(3):647-654
pubmed: 30712921
Amyloid. 2018 Dec;25(4):215-219
pubmed: 30614283
Front Cardiovasc Med. 2020 Feb 25;7:22
pubmed: 32158768
Acta Pathol Microbiol Scand A. 1977 Nov;85(6):761-7
pubmed: 602763
Clin J Am Soc Nephrol. 2013 Oct;8(10):1718-24
pubmed: 23886566
J Clin Endocrinol Metab. 2005 Apr;90(4):2244-9
pubmed: 15671108
Eur J Intern Med. 2017 Apr;39:e18-e20
pubmed: 28214252
JAMA. 1999 Dec 8;282(22):2131-5
pubmed: 10591334
Diabetologia. 2005 Mar;48(3):519-28
pubmed: 15729583